All anti-CD20 monoclonal antibodies have similar efficacy and risks: No
Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › fagfællebedømt
Standard
All anti-CD20 monoclonal antibodies have similar efficacy and risks : No. / Sellebjerg, Finn; Romme Christensen, Jeppe.
I: Multiple Sclerosis Journal, Bind 28, Nr. 12, 2022, s. 1845-1846.Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › fagfællebedømt
Harvard
Sellebjerg, F & Romme Christensen, J 2022, 'All anti-CD20 monoclonal antibodies have similar efficacy and risks: No', Multiple Sclerosis Journal, bind 28, nr. 12, s. 1845-1846. https://doi.org/10.1177/13524585221103729
APA
Sellebjerg, F., & Romme Christensen, J. (2022). All anti-CD20 monoclonal antibodies have similar efficacy and risks: No. Multiple Sclerosis Journal, 28(12), 1845-1846. https://doi.org/10.1177/13524585221103729
Vancouver
Sellebjerg F, Romme Christensen J. All anti-CD20 monoclonal antibodies have similar efficacy and risks: No. Multiple Sclerosis Journal. 2022;28(12):1845-1846. https://doi.org/10.1177/13524585221103729
Author
Bibtex
@article{90020a846fa448419ecc0ac55e73e7cf,
title = "All anti-CD20 monoclonal antibodies have similar efficacy and risks: No",
author = "Finn Sellebjerg and {Romme Christensen}, Jeppe",
year = "2022",
doi = "10.1177/13524585221103729",
language = "English",
volume = "28",
pages = "1845--1846",
journal = "Multiple Sclerosis Journal",
issn = "1352-4585",
publisher = "SAGE Publications",
number = "12",
}
RIS
TY - JOUR
T1 - All anti-CD20 monoclonal antibodies have similar efficacy and risks
T2 - No
AU - Sellebjerg, Finn
AU - Romme Christensen, Jeppe
PY - 2022
Y1 - 2022
U2 - 10.1177/13524585221103729
DO - 10.1177/13524585221103729
M3 - Comment/debate
C2 - 36124837
AN - SCOPUS:85138150352
VL - 28
SP - 1845
EP - 1846
JO - Multiple Sclerosis Journal
JF - Multiple Sclerosis Journal
SN - 1352-4585
IS - 12
ER -
ID: 321283638